Department of Physiology and Pharmacology, Neuropharmacology Laboratory, Drug Research and Development Center, School of Medicine, Federal University of Ceará, Fortaleza, Brazil.
Department of Physiology and Pharmacology, Neuropharmacology Laboratory, Drug Research and Development Center, School of Medicine, Federal University of Ceará, Fortaleza, Brazil,
Neuropsychobiology. 2022;81(1):28-38. doi: 10.1159/000515929. Epub 2021 Apr 29.
Depression is a common, chronic, and often recurrent serious mood disorder. Conventional antidepressants present limitations that stimulate the search for new drugs. Antioxidant and neuroprotective substances are potential antidepressant agents. In this context, riparin I (RIP I) has presented promising results, emerging as a potential source of a new therapeutic drug. In this study, the antidepressant effect of RIP I was evaluated in an animal model of depression induced by corticosterone (CORT). The involvement of neuroprotective and antioxidant mechanisms in the generation of this effect was also assessed.
Female mice were submitted to CORT for 21 days and treated with RIP I in the last 7 days. Behavioral and neurochemical analyses were performed.
The administration of RIP I reversed the depressive and psychotic-like behavior, as well as the cognitive impairment caused by CORT, in addition to regulating oxidative stress parameters and BDNF levels in depression-related brain areas.
These findings suggest that RIP I can be a strong candidate for drugs in the treatment of depression.
抑郁症是一种常见的、慢性的、常常反复发作的严重情绪障碍。传统的抗抑郁药存在局限性，这刺激了人们对新药的探索。抗氧化和神经保护物质是有潜力的抗抑郁药物。在这种情况下，利培酮 I（RIP I）表现出了有前景的结果，它成为一种新的治疗药物的潜在来源。在这项研究中，我们评估了 RIP I 在皮质酮（CORT）诱导的抑郁动物模型中的抗抑郁作用，并评估了神经保护和抗氧化机制在产生这种作用中的参与。
雌性小鼠接受 CORT 处理 21 天，并在最后 7 天用 RIP I 进行治疗。进行了行为和神经化学分析。
RIP I 的给药逆转了 CORT 引起的抑郁和精神病样行为以及认知障碍，此外还调节了与抑郁相关脑区的氧化应激参数和 BDNF 水平。
这些发现表明，RIP I 可能是治疗抑郁症的药物的有力候选药物。
